The Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), a leader in the pharmaceutical sector in the Kingdom, announced a new strategic step represented by the establishment of a wholly owned subsidiary company under the name “SPIMACO Bio Company”.
In an official statement published on the Saudi Stock Exchange website “Tadawul”, the company explained that this establishment comes as a culmination of its ambitious strategic directions towards expansion in the fields of high value-added pharmaceutical industries, specifically the biological, genetic and cellular pharmaceutical sector, which is the future of modern medicine.
The importance of the shift towards biopharmaceuticals
The establishment of Spimaco Bio aligns with the company's updated strategy to strengthen its leadership and strong presence in the biopharmaceutical sector. This move aims to diversify the product portfolio to include advanced treatments for intractable and chronic diseases, thus supporting the company's sustainable long-term growth.
This step is particularly important given the complex nature of biological and gene therapies, which rely on advanced biotechnologies entirely different from traditional chemical pharmaceuticals. This sector is experiencing rapid global growth due to its effectiveness in treating diseases such as cancer, autoimmune diseases, and rare genetic disorders, making investment in it essential to keep pace with global medical advancements.
Supporting the Kingdom's Vision 2030 and pharmaceutical security
The establishment of the new company is not solely driven by commercial objectives, but also directly contributes to achieving the goals of the Kingdom's Vision 2030 and the National Industrial Development and Logistics Program (NIDLP). The Kingdom is actively striving to increase the local content in the healthcare sector and achieve pharmaceutical security by localizing advanced and complex pharmaceutical industries, thus reducing its complete reliance on imports.
This project will contribute to transferring knowledge and leading technologies to the Kingdom, and training national cadres on the latest biotechnology, thus enhancing Saudi Arabia’s position as a regional center for innovative pharmaceutical industries in the Middle East and North Africa region.
Financial impact and next steps
Regarding financial matters, Spimaco Pharmaceuticals indicated that there is no material financial impact resulting from the incorporation process at this time. It affirmed its commitment to transparency and to disclosing any material financial developments that may occur in the future, in accordance with applicable regulations and instructions.
The company noted that “Spimaco Bio” will commence its operational activities as soon as all regulatory procedures are completed and the necessary licenses and approvals are obtained from the competent authorities, foremost among them the General Authority for Food and Drug and the Ministry of Industry and Mineral Resources.
